May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Differential Expression of VEGF Receptor-2 in Retina of Diabetes Mellitus Type 1 and Type 2 Patients
Author Affiliations & Notes
  • A. N. Witmer
    Academic Medical Center, Amsterdam, The Netherlands
    Ophthalmology,
  • Ocular Angiogenesis Group AMC
    Academic Medical Center, Amsterdam, The Netherlands
  • I. Klaassen
    Academic Medical Center, Amsterdam, The Netherlands
    Ophthalmology,
    Cell Biology and Histology,
  • J. Aten
    Academic Medical Center, Amsterdam, The Netherlands
    Pathology,
  • C. J. F. van Noorden
    Academic Medical Center, Amsterdam, The Netherlands
    Cell Biology and Histology,
  • R. O. Schlingemann
    Academic Medical Center, Amsterdam, The Netherlands
    Ophthalmology,
    Cell Biology and Histology,
  • Footnotes
    Commercial Relationships A.N. Witmer, None; I. Klaassen, None; J. Aten, None; C.J.F. van Noorden, None; R.O. Schlingemann, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1367. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. N. Witmer, Ocular Angiogenesis Group AMC, I. Klaassen, J. Aten, C. J. F. van Noorden, R. O. Schlingemann; Differential Expression of VEGF Receptor-2 in Retina of Diabetes Mellitus Type 1 and Type 2 Patients. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1367.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Diabetic retinopathy (DR) manifests differently in type 1 and type 2 diabetes mellitus (DM1 and 2) patients, but these differences are poorly defined and unexplained. In the pathogenesis of DR, vascular endothelial growth factor (VEGF)-A signaling via VEGF receptor-2 (VEGFR2, Flk-1, KDR) in vascular and non-vascular retinal cells is crucial. In an attempt to further define differences between DR in DM1 and DM2, we investigated VEGFR2 expression in human retina with preclinical or manifest DR.

Methods:: Human eyes were collected from 9 DM1 donors, 28 DM2 donors (17 on insulin) and 18 non-diabetic donors. Retinal RNA was isolated and transcription levels of VEGFR2 were measured by real-time quantitative RT-PCR analysis. Immunohistochemistry was used for comparison.

Results:: Retinal levels of VEGFR2 mRNA were found to be increased in DM1 (p=0.08) and decreased in DM2 (p=0.015), especially in retina of patients with DM2 who did not use insulin (3.5-fold, p=0.007), when compared to non-diabetic controls. Microvascular VEGFR2 protein levels were higher in DM2 as compared to controls. In both DM1 and DM2, increased VEGFR2 expression levels were found in the whole retina with manifest DR compared to preclinical DR.

Conclusions:: Our study has identified important differences in expression levels of VEGFR2 in the human neural retina of DM1 and DM2 patients, and shows increased vascular expression during progression of DR. These differences may be relevant for understanding differences in pathogenesis of DR in both types of diabetes.

Keywords: diabetic retinopathy • growth factors/growth factor receptors • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×